+1 347 708 0418
Targeted Drug VEGF Inhibitors for NSCLC market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Targeted Drug VEGF Inhibitors for NSCLC market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Bevacizumab
Other
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Company
Roche
Pfizer
Allergan
Amgen
Biocon
Reliance Lifesciences
Beaconpharma
Celgene Corporation
Fujifilm Kyowa Kirin Biologics
Hetero Drugs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Bevacizumab
1.2.3 Other
1.3 Market by Application
1.3.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Perspective (2017-2028)
2.2 Targeted Drug VEGF Inhibitors for NSCLC Growth Trends by Region
2.2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Region (2017-2022)
2.2.3 Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028)
2.3 Targeted Drug VEGF Inhibitors for NSCLC Market Dynamics
2.3.1 Targeted Drug VEGF Inhibitors for NSCLC Industry Trends
2.3.2 Targeted Drug VEGF Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug VEGF Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug VEGF Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Revenue (2017-2022)
3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Players (2017-2022)
3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drug VEGF Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2021
3.5 Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Area Served
3.6 Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service
3.7 Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug VEGF Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Type (2017-2022)
4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028)
5 Targeted Drug VEGF Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Application (2017-2022)
5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2017-2028)
6.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
6.2.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022)
6.2.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028)
6.2.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2017-2028)
6.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
6.3.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022)
6.3.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028)
6.3.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2017-2028)
6.4 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
6.4.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022)
6.4.2 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2017-2028)
7.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
7.2.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022)
7.2.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028)
7.2.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2017-2028)
7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
7.3.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022)
7.3.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028)
7.3.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2017-2028)
7.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
7.4.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022)
7.4.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size (2017-2028)
8.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
8.2.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2017-2028)
8.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
8.3.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2017-2028)
8.4 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region
8.4.1 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2017-2028)
9.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
9.2.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022)
9.2.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028)
9.2.3 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2017-2028)
9.3 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
9.3.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022)
9.3.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028)
9.3.3 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2017-2028)
9.4 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
9.4.1 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022)
9.4.2 Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size (2017-2028)
10.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
10.2.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2017-2028)
10.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
10.3.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2017-2028)
10.4 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
10.4.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.1.4 Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.2.4 Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.2.5 Pfizer Recent Developments
11.3 Allergan
11.3.1 Allergan Company Details
11.3.2 Allergan Business Overview
11.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.3.4 Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.3.5 Allergan Recent Developments
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.4.4 Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.4.5 Amgen Recent Developments
11.5 Biocon
11.5.1 Biocon Company Details
11.5.2 Biocon Business Overview
11.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.5.4 Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.5.5 Biocon Recent Developments
11.6 Reliance Lifesciences
11.6.1 Reliance Lifesciences Company Details
11.6.2 Reliance Lifesciences Business Overview
11.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.6.4 Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.6.5 Reliance Lifesciences Recent Developments
11.7 Beaconpharma
11.7.1 Beaconpharma Company Details
11.7.2 Beaconpharma Business Overview
11.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.7.4 Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.7.5 Beaconpharma Recent Developments
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.8.4 Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.8.5 Celgene Corporation Recent Developments
11.9 Fujifilm Kyowa Kirin Biologics
11.9.1 Fujifilm Kyowa Kirin Biologics Company Details
11.9.2 Fujifilm Kyowa Kirin Biologics Business Overview
11.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.9.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.9.5 Fujifilm Kyowa Kirin Biologics Recent Developments
11.10 Hetero Drugs
11.10.1 Hetero Drugs Company Details
11.10.2 Hetero Drugs Business Overview
11.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Introduction
11.10.4 Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
11.10.5 Hetero Drugs Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Bevacizumab
Table 3. Key Players of Other
Table 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region (2017-2022)
Table 8. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region (2023-2028)
Table 10. Targeted Drug VEGF Inhibitors for NSCLC Market Trends
Table 11. Targeted Drug VEGF Inhibitors for NSCLC Market Drivers
Table 12. Targeted Drug VEGF Inhibitors for NSCLC Market Challenges
Table 13. Targeted Drug VEGF Inhibitors for NSCLC Market Restraints
Table 14. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Players (2017-2022)
Table 16. Global Top Targeted Drug VEGF Inhibitors for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2021)
Table 17. Ranking of Global Top Targeted Drug VEGF Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service
Table 21. Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2017-2022)
Table 25. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2023-2028)
Table 27. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Application (2017-2022)
Table 29. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Share by Application (2023-2028)
Table 31. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Targeted Drug VEGF Inhibitors for NSCLC Product
Table 64. Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 65. Roche Recent Developments
Table 66. Pfizer Company Details
Table 67. Pfizer Business Overview
Table 68. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product
Table 69. Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 70. Pfizer Recent Developments
Table 71. Allergan Company Details
Table 72. Allergan Business Overview
Table 73. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product
Table 74. Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 75. Allergan Recent Developments
Table 76. Amgen Company Details
Table 77. Amgen Business Overview
Table 78. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product
Table 79. Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 80. Amgen Recent Developments
Table 81. Biocon Company Details
Table 82. Biocon Business Overview
Table 83. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product
Table 84. Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 85. Biocon Recent Developments
Table 86. Reliance Lifesciences Company Details
Table 87. Reliance Lifesciences Business Overview
Table 88. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product
Table 89. Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 90. Reliance Lifesciences Recent Developments
Table 91. Beaconpharma Company Details
Table 92. Beaconpharma Business Overview
Table 93. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product
Table 94. Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 95. Beaconpharma Recent Developments
Table 96. Celgene Corporation Company Details
Table 97. Celgene Corporation Business Overview
Table 98. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product
Table 99. Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 100. Celgene Corporation Recent Developments
Table 101. Fujifilm Kyowa Kirin Biologics Company Details
Table 102. Fujifilm Kyowa Kirin Biologics Business Overview
Table 103. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product
Table 104. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 105. Fujifilm Kyowa Kirin Biologics Recent Developments
Table 106. Hetero Drugs Company Details
Table 107. Hetero Drugs Business Overview
Table 108. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product
Table 109. Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
Table 110. Hetero Drugs Recent Developments
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type: 2021 VS 2028
Figure 2. Bevacizumab Features
Figure 3. Other Features
Figure 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2021 VS 2028
Figure 5. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 6. Adenocarcinoma of NSCLC Case Studies
Figure 7. Large Cell Carcinoma of NSCLC Case Studies
Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered
Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Region: 2021 VS 2028
Figure 12. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players in 2021
Figure 13. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2021
Figure 15. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 17. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 18. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 19. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 23. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 24. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 25. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Region (2017-2028)
Figure 35. China Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 43. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 45. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Country (2017-2028)
Figure 51. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Roche Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 55. Pfizer Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 56. Allergan Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 57. Amgen Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 58. Biocon Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 59. Reliance Lifesciences Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 60. Beaconpharma Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 61. Celgene Corporation Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 62. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 63. Hetero Drugs Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Buy
